The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui; Hong-Thinh Lai; Thanh-Lam Nguyen; Thuy-Duong Vu; Nhat-Le Bui; Van-Hung Nguyen; Thi-To-Chau Tran; Thi-Phuong-Thuy Nguyen; Thi-Ngoc-Lan Nguyen; Jaffar A. Al-Tawfiq; Dinh-Toi Chu;

Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting Sara Marsal Barril; Mª Auxiliadora Martin-Martinez; Francisco Javier Blanco-Garcia; Antonio Fernández-Nebro; Rosario García de Vicuña; Jesús Tornero-Molina; Fernando Sánchez-Alonso; Marta Novella-Navarro; Alejandro Escudero-Contreras; Juan José Alegre-Sancho; Ana Urruticoechea-Arana; Maria Sagrario Bustabad-Reyes; Pilar Trenor-Larraz; Trinidad Pérez-Sandoval; Maria Isabel Tevar-Sánchez; Jesús T. Sánchez-Costa; Enrique Raya-Álvarez;

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández; Elena Villamañán; Inmaculada Jiménez-Nácher; Francisco Moreno; Chamaida Plasencia; Francisco Gayá; Alicia Herrero; Alejandro Balsa;